Signal transduction pathways US Medical PG Practice Questions and MCQs
Practice US Medical PG questions for Signal transduction pathways. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Signal transduction pathways US Medical PG Question 1: Which receptor type mediates the slow phase of synaptic transmission in autonomic ganglia?
- A. Muscarinic (M3)
- B. Muscarinic (M2)
- C. Muscarinic (M1) (Correct Answer)
- D. Nicotinic (N2)
Signal transduction pathways Explanation: ***Muscarinic (M1)***
- **M1 receptors** are **Gq-protein coupled receptors** that activate phospholipase C, leading to increased intracellular calcium and diacylglycerol, which mediates the slow excitatory postsynaptic potential in autonomic ganglia.
- This activation results in a **slow depolarization** that prolongs the excitability of ganglionic neurons after the initial fast synaptic transmission.
*Muscarinic (M3)*
- **M3 receptors** are primarily found on **smooth muscle**, glands, and endothelium, mediating contraction, secretion, and vasodilation, respectively.
- While also **Gq-protein coupled**, their role in autonomic ganglia is not the main mediator of the slow phase of synaptic transmission.
*Muscarinic (M2)*
- **M2 receptors** are **Gi-protein coupled receptors** mainly found in the heart, mediating decreased heart rate and contractility.
- In autonomic ganglia, M2 receptors could have a modulatory role, but they are not responsible for the slow excitatory phase of synaptic transmission.
*Nicotinic (N2)*
- **Nicotinic N2 receptors** (also known as **NN or neuronal nicotinic receptors**) mediate the **fast excitatory postsynaptic potential** (EPSP) in autonomic ganglia by opening ion channels.
- This leads to rapid depolarization and action potential generation, which is distinct from the **slower, prolonged phase** of transmission.
Signal transduction pathways US Medical PG Question 2: A 21-year-old man presents to the office for a follow-up visit. He was recently diagnosed with type 1 diabetes mellitus after being hospitalized for diabetic ketoacidosis following a respiratory infection. He is here today to discuss treatment options available for his condition. The doctor mentions a recent study in which researchers have developed a new version of the insulin pump that appears efficacious in type 1 diabetics. They are currently comparing it to insulin injection therapy. This new pump is not yet available, but it looks very promising. At what stage of clinical trials is this current treatment most likely at?
- A. Phase 0
- B. Phase 2
- C. Phase 3 (Correct Answer)
- D. Phase 1
- E. Phase 4
Signal transduction pathways Explanation: ***Phase 3***
- **Phase 3 trials** involve large-scale studies comparing the new treatment to standard therapy or placebo, often across multiple centers.
- The scenario describes a "new version of the insulin pump" being compared to "insulin injection therapy," indicating a definitive comparison for efficacy and safety against existing treatments.
*Phase 0*
- **Phase 0 trials** are exploratory, small-scale studies (10-15 subjects) using micro-doses to gather preliminary data on pharmacodynamics and pharmacokinetics, not efficacy comparisons.
- They are typically conducted very early in drug development, examining if the drug behaves as expected in humans.
*Phase 2*
- **Phase 2 trials** evaluate the efficacy and further assess safety of a new treatment in a larger group of patients (tens to hundreds).
- While they assess efficacy, they usually don't involve direct comparison with an established standard therapy on the scale implied by the question, which is typically reserved for Phase 3.
*Phase 1*
- **Phase 1 trials** primarily focus on safety, dosage, and side effects in a small group of healthy volunteers or patients with the condition (20-100 subjects).
- These trials are not designed to assess a treatment's efficacy against an existing therapy.
*Phase 4*
- **Phase 4 trials** occur after a drug or device has been approved and marketed, focusing on long-term safety, effectiveness in diverse populations, and new indications.
- The described pump "is not yet available," indicating it has not reached the market and thus is not in Phase 4.
Signal transduction pathways US Medical PG Question 3: A 55-year-old man comes to the physician with a 3-month history of headache, periodic loss of vision, and easy bruising. Physical examination shows splenomegaly. His hemoglobin concentration is 13.8 g/dL, leukocyte count is 8000/mm3, and platelet count is 995,000/mm3. Bone marrow biopsy shows markedly increased megakaryocytes with hyperlobulated nuclei. Genetic analysis shows upregulation of the JAK-STAT genes. The pathway encoded by these genes is also physiologically responsible for signal transmission of which of the following hormones?
- A. Oxytocin
- B. Adrenocorticotropic hormone
- C. Prolactin (Correct Answer)
- D. Cortisol
- E. Insulin
Signal transduction pathways Explanation: ***Prolactin***
- Prolactin utilizes the **JAK-STAT signaling pathway** to exert its effects on target cells, particularly in the mammary glands.
- The **JAK-STAT pathway** is crucial for cell growth, differentiation, and immune response, and its dysregulation is linked to myeloproliferative disorders like those involving megakaryocyte proliferation.
*Oxytocin*
- Oxytocin primarily acts through **G-protein coupled receptors** that activate the phospholipase C/inositol triphosphate pathway, not the JAK-STAT pathway.
- Its main roles involve uterine contraction and milk ejection, which are distinct from the cellular proliferation regulated by JAK-STAT.
*Adrenocorticotropic hormone*
- ACTH binds to **G-protein coupled receptors** in the adrenal cortex, stimulating adenylyl cyclase and increasing cAMP levels.
- This mechanism of action is distinct from the tyrosine kinase activity characteristic of the JAK-STAT pathway.
*Cortisol*
- Cortisol, a steroid hormone, primarily acts via **intracellular glucocorticoid receptors** that translocate to the nucleus to regulate gene transcription.
- Its signaling mechanism involves direct gene regulation rather than a membrane-bound receptor-kinase cascade like JAK-STAT.
*Insulin*
- Insulin signals through a **receptor tyrosine kinase**, which, upon binding, autophosphorylates and initiates a cascade involving IRS proteins and the PI3K/Akt and MAPK pathways.
- While it involves tyrosine phosphorylation, it is distinct from the JAK-STAT pathway, which is primarily activated by cytokine and growth hormone type I receptors.
Signal transduction pathways US Medical PG Question 4: A group of scientists is studying the mechanism of action of various pancreatic hormones in rats. The scientists studied hormone A, which is secreted by the β-cells of the pancreas, and found that hormone A binds to a complex dimeric receptor on the cell membrane and exerts its effects via phosphorylation and subsequent downstream signaling that includes dephosphorylation of different intracellular proteins. Now they are studying hormone B, which is secreted by the α-cells and antagonizes the actions of hormone A. Which 2nd messenger system would hormone B utilize to exert its cellular effects?
- A. Direct cytoplasmic receptor binding
- B. Phospholipase C
- C. Tyrosine kinase
- D. Direct nuclear receptor binding
- E. Adenylyl cyclase-cyclic AMP (Correct Answer)
Signal transduction pathways Explanation: ***Adenylyl cyclase-cyclic AMP***
- Hormone B is **glucagon**, secreted by pancreatic α-cells, which antagonizes the effects of insulin (hormone A). Glucagon primarily acts through a **G protein-coupled receptor** that activates **adenylyl cyclase**, leading to an increase in intracellular **cyclic AMP (cAMP)**.
- Increased cAMP then activates **protein kinase A (PKA)**, which phosphorylates various intracellular proteins to promote **glycogenolysis** and **gluconeogenesis**, thereby raising blood glucose levels.
*Direct cytoplasmic receptor binding*
- This mechanism is characteristic of **steroid hormones**, which are lipid-soluble and can diffuse across the cell membrane to bind to receptors in the cytoplasm.
- Pancreatic hormones like glucagon are **peptide hormones**, which are water-soluble and typically bind to cell surface receptors.
*Phospholipase C*
- Activation of **phospholipase C (PLC)** leads to the production of **inositol triphosphate (IP3)** and **diacylglycerol (DAG)**, which mobilize intracellular calcium and activate protein kinase C, respectively.
- While some G protein-coupled receptors activate PLC, **glucagon's primary signaling pathway** involves adenylyl cyclase.
*Tyrosine kinase*
- **Tyrosine kinase receptors** are often associated with growth factors and insulin (hormone A) signaling, leading to phosphorylation of tyrosine residues on target proteins.
- Glucagon's receptor is a **G protein-coupled receptor**, not a receptor tyrosine kinase, and its actions are mediated through serine/threonine phosphorylation via PKA.
*Direct nuclear receptor binding*
- This mechanism is typical for **steroid hormones** and **thyroid hormones**, which are lipid-soluble and bind to receptors in the nucleus to directly influence gene transcription.
- As a peptide hormone, glucagon binds to cell surface receptors and does not directly interact with nuclear receptors.
Signal transduction pathways US Medical PG Question 5: A 69-year-old woman comes to the clinic for an annual well exam. She reports no significant changes to her health except for an arm fracture 3 weeks ago while she was lifting some heavy bags. Her diabetes is well controlled with metformin. She reports some vaginal dryness that she manages with adequate lubrication. She denies any weight changes, fevers, chills, palpitations, nausea/vomiting, incontinence, or bowel changes. A dual-energy X-ray absorptiometry (DEXA) scan was done and demonstrated a T-score of -2.7. She was subsequently prescribed a selective estrogen receptor modulator, in addition to vitamin and weight-bearing exercises, for the management of her symptoms. What is the mechanism of action of the prescribed medication?
- A. Estrogen antagonist in cervix and agonist in bone
- B. Estrogen agonist in bone and breast
- C. Estrogen antagonist in breast and agonist in bone (Correct Answer)
- D. Partial estrogen agonist in endometrium and bone
- E. Partial estrogen agonist in bone and antagonist in cervix
Signal transduction pathways Explanation: ***Estrogen antagonist in breast and agonist in bone***
- Selective estrogen receptor modulators (SERMs) like **raloxifene** act as **estrogen agonists in bone**, helping to prevent osteoporosis by increasing bone mineral density.
- They also act as **estrogen antagonists in breast tissue**, which can reduce the risk of breast cancer in high-risk postmenopausal women.
- This is the mechanism of the medication prescribed for this patient's osteoporosis (T-score -2.7).
*Estrogen antagonist in cervix and agonist in bone*
- While SERMs are **agonists in bone**, they do not typically have significant antagonistic effects on the cervix, which is not a primary target for their therapeutic action or side effect profile.
- The primary antagonism is observed in breast tissue, not the cervix.
*Estrogen agonist in bone and breast*
- This describes the action of **estrogen replacement therapy (ERT)**, which increases breast cancer risk, whereas SERMs are designed to avoid this by being antagonists in breast tissue.
- The goal of SERMs is to achieve the beneficial bone effects of estrogen without the undesirable estrogenic effects on breast tissue.
*Partial estrogen agonist in endometrium and bone*
- Some SERMs, particularly **tamoxifen**, can act as a **partial estrogen agonist in the endometrium**, which can increase the risk of endometrial hyperplasia or cancer.
- However, raloxifene (a common SERM for osteoporosis) is typically **neutral or minimally agonistic** on the endometrium, and the primary description here is for its breast and bone effects.
*Partial estrogen agonist in bone and antagonist in cervix*
- SERMs are indeed **agonists in bone**, but their antagonistic action is primarily in the breast, not the cervix.
- The cervix is not a key target for either agonist or antagonist effects in the context of SERM therapeutic use for osteoporosis and breast cancer risk reduction.
More Signal transduction pathways US Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
